bfe67bb53c3c532ef4237fa3323691ae27404769
¶ Gene and Protein Structure
| Property |
Value |
| Gene Symbol |
TNFRSF13C |
| Chromosomal Location |
22q13.1 |
| UniProt ID |
Q9Y239 |
| Protein Length |
184 amino acids (human) |
| Protein Type |
Type I transmembrane receptor |
| Molecular Weight |
~19.2 kDa |
| Domains |
Single cysteine-rich domain (CRD) in extracellular region, no death domain |
BAFFR is a relatively small TNF receptor with a single extracellular cysteine-rich domain (CRD) that mediates BAFF binding. Unlike other TNFR family members such as TNFR1 or DR4/DR5, BAFFR lacks a death domain and signals exclusively through the non-canonical NF-κB pathway (NF-κB2), making it a survival and maturation receptor rather than a death receptor.
¶ B Cell Survival and Homeostasis
BAFFR is the primary sensor for B cell survival in the periphery:
- B cell survival signal: BAFF binding to BAFFR provides critical survival signals for transitional and mature B cells. Mice lacking BAFFR (Tnfrsf13c knockout) or BAFF have severely reduced mature B cell numbers
- B cell maturation: BAFFR is essential for the transition of transitional B cells to mature B cells in the spleen
- Marginal zone B cells: BAFFR is particularly important for the survival and maintenance of marginal zone B cells
- T cell-independent antibody responses: BAFFR signaling supports B cell responses to T cell-independent antigens
BAFFR signals through the non-canonical NF-κB pathway:
- BAFF binding: BAFF (a homotrimer) binds to BAFFR (requires 3 BAFFR molecules per BAFF trimer)
- NIK activation: BAFFR recruits TRAF2/TRAF3 adaptor complex; upon ligand binding, TRAF3 is degraded, releasing NIK (NF-κB-inducing kinase)
- NF-κB2 processing: NIK phosphorylates and activates IKKα, which then phosphorylates the NF-κB2 precursor p100
- p100 processing: Phosphorylated p100 is ubiquitinated and processed to p52
- Gene transcription: p52 forms heterodimers with RelB and translocates to the nucleus to drive expression of anti-apoptotic genes (Bcl-2, Bcl-xL, c-IAP1/2)
¶ BAFF Ligands and Receptors
| Ligand |
Receptor |
Signaling |
Function |
| BAFF |
BAFFR (TNFRSF13C) |
Non-canonical NF-κB2 |
B cell survival, maturation |
| BAFF |
TACI (TNFRSF13B) |
Both canonical and non-canonical NF-κB |
Regulation, plasma cell survival |
| BAFF |
BCMA (TNFRSF17) |
Non-canonical NF-κB2 |
Plasma cell survival |
| APRIL |
TACI, BCMA |
Non-canonical NF-κB2 |
Plasma cell survival |
¶ CNS Expression and Sources
BAFF is produced within the CNS by multiple cell types:
- Astrocytes: Astrocytes synthesize and secrete BAFF, particularly in response to inflammatory signals. BAFF expression is upregulated in multiple sclerosis lesions.
- Microglia: Microglia can produce BAFF upon stimulation. Gangliosides stimulate microglia to synthesize and release BAFF through JAK-STAT signaling pathways (STAT1 and STAT3), which in turn modulates microglial activation and cytokine release (IL-6, TNF-α, IL-10).
- Infiltrating immune cells: B cells and macrophages that infiltrate the CNS can also be sources of BAFF
- Microglia: Microglia express BAFFR on their surface, making them responsive to BAFF
- CNS B cells: Infiltrating and resident B cells in the CNS express BAFFR
- Astrocytes: Some astrocyte populations may express BAFFR under inflammatory conditions
BAFFR plays a critical role in multiple sclerosis through its regulation of B cell survival and activation within the CNS.
- B cell survival in CNS: BAFF produced by astrocytes and microglia provides survival signals to B cells infiltrating the CNS, allowing autoreactive B cell clones to persist
- Antibody production: BAFFR-mediated survival supports long-lived plasma cells that produce oligoclonal IgG bands in CSF of MS patients
- Antigen presentation: BAFFR supports B cell survival, enabling B cells to serve as antigen-presenting cells that activate myelin-reactive T cells
- T cell help: B cells responding to BAFF signals can provide help to pathogenic T cells
| Agent |
Mechanism |
Clinical Status |
| Belimumab |
Anti-BAFF monoclonal antibody |
FDA-approved for SLE |
| Atacicept |
TACI-Fc fusion protein (blocks BAFF + APRIL) |
Phase 2/3 MS (terminated - worsening observed) |
| BAFFR antagonist antibodies |
Block BAFF-BAFFR interaction |
Preclinical |
The failed atacicept trials in MS highlighted the complex role of BAFF in CNS autoimmunity -- BAFF/APRIL blockade may have removed a protective mechanism in some patient subgroups.
While BAFFR's primary neuroimmune link is to MS, emerging evidence suggests roles in Alzheimer's disease:
- B cell infiltration: Peripheral B cells may infiltrate the CNS in AD, where BAFFR signaling supports their survival and activity
- Microglial modulation: Microglial BAFFR signaling may influence the neuroinflammatory profile in AD
- Humoral immunity: BAFFR-dependent B cell responses may contribute to neuroinflammation through antibody deposition and immune complex formation
- BAFF levels are elevated in AD patient serum and CSF in some studies
- BAFFR-expressing B cells accumulate in AD brain tissue
- The role of BAFF/BAFFR in AD remains less well-characterized than in MS
- Primary CNS lymphoma (PCNSL) cells express BAFFR and depend on BAFF for survival
- BAFF/BAFFR signaling may contribute to the proliferation and persistence of malignant B cells in the CNS
- BAFFR signaling supports survival of autoreactive B cells that produce pathogenic antibodies (e.g., anti-NMDA receptor antibodies)
- Blocking BAFFR may reduce pathogenic antibody production
- Microglial BAFF expression is induced by inflammatory stimuli
- BAFFR-mediated microglial responses may contribute to neuroinflammation in PD
BAFFR is a validated target for B cell-directed therapies in systemic autoimmunity:
- Belimumab: Monoclonal antibody that neutralizes BAFF, approved for systemic lupus erythematosus (SLE). Does not directly target BAFFR but blocks the ligand
- Obinutuzumab: Anti-CD20 antibody that depletes B cells (downstream of BAFFR effects)
- BAFFR-specific antagonists: Under development for autoimmune diseases
- Blood-brain barrier penetration: Large biologics may not adequately reach CNS B cells
- Complexity of BAFF biology: Both BAFFR and TACI signaling affect B cells differently
- Homeostatic role: BAFFR blockade may affect beneficial B cell populations
| Partner |
Interaction Type |
Function |
| BAFF (TNFSF13B) |
Ligand binding |
Primary activating ligand |
| TRAF2 |
Adaptor protein |
Signal transduction |
| TRAF3 |
Adaptor protein |
Negative regulation (in absence of ligand) |
| NIK (MAP3K14) |
Downstream kinase |
NF-κB2 pathway activation |
| IKKα |
Kinase |
NF-κB2 processing |
| NF-κB2 (NFKB2) |
Transcription factor |
Gene expression (survival genes) |